Trial Profile

A Phase I Clinical Study of Brevenal in Cystic Fibrosis (CF) Patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brevenal (Primary)
Indications Cystic fibrosis
Focus Adverse reactions
Sponsors Silurian Pharmaceuticals

Most Recent Events

30 May 2019 New trial record
04 Apr 2018 According to a Silurian Pharmaceuticals media release, the company hope to launch this phase 1 clinical study, next year, following the conclusion of all pre-clinical safety toxicology studies.
08 Oct 2015 According to a Silurian Pharmaceuticals media release, the company is looking forward to advance brevenal into the clinic within the next 12-16 months.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com